{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:07:43Z","timestamp":1789391263335,"version":"build-2803163510"},"reference-count":34,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: In China, the current national immunisation schedule extends only to 4 years of age, and no polio booster dose is recommended for adolescents or adults, with data on immunogenicity and safety in these populations lacking. This phase IV trial evaluated the immunogenicity and safety of a single booster dose of Sabin-strain inactivated poliovirus vaccine (sIPV) in Chinese adolescents and adults. Methods: This phase IV, open-label trial enrolled 120 healthy participants, comprising 60 adolescents aged 7\u201317 years and 60 adults aged 18\u201350 years, who received a single booster dose of sIPV. Participants were enrolled and vaccinated in Gansu Province, China, between 21 October and 1 November 2025. Immunogenicity was assessed by neutralising antibody titres against poliovirus types 1, 2, and 3 before and 30 days post-vaccination. Safety was evaluated through monitoring of adverse events throughout the 30-day follow-up period. Results: Following a single sIPV booster dose, seropositivity rates reached 100% for all three poliovirus serotypes in both age groups. Post-vaccination geometric mean titres (GMTs) for types 1, 2, and 3 were 1748.29, 3961.77, and 2089.08 in adolescents, and 1902.58, 4434.39, and 2256.16 in adults, respectively, with no significant between-group differences. Seroconversion rates for type 3 were significantly higher in adults than in adolescents (98.33% vs. 86.67%, p = 0.032). Geometric mean increases (GMIs) were significantly higher in adults for type 1 (72.12 vs. 28.10, p = 0.008) and type 3 (316.14 vs. 45.56, p &lt; 0.001). The vaccine was well tolerated; vaccine-related adverse events were reported in 17.50% of participants, all mild to moderate, with no vaccine-related serious adverse events. Conclusions: A single booster dose of sIPV induced robust neutralising antibody responses across all three poliovirus serotypes in both adolescents and adults, with a favourable safety profile. Adults with lower baseline immunity derived proportionally greater fold-increases in antibody titres.<\/jats:p>","DOI":"10.3390\/vaccines14090808","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:09:51Z","timestamp":1789387791000},"page":"808","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenicity and Safety of a Single Booster Dose of Sabin-Strain Inactivated Poliovirus Vaccine in Adolescents and Adults: A Phase IV, Open-Label Trial"],"prefix":"10.3390","volume":"14","author":[{"given":"Xiaoshu","family":"Zhang","sequence":"first","affiliation":[{"name":"Gansu Provincial Center for Disease Control and Prevention, Gansu Provincial Academy of Preventive Medicine, Lanzhou 730300, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7804-3786","authenticated-orcid":false,"given":"Weixiao","family":"Han","sequence":"additional","affiliation":[{"name":"Sinovac Biotech Co., Ltd., Beijing 100085, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Sinovac Biotech Co., Ltd., Beijing 100085, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tang","sequence":"additional","affiliation":[{"name":"Gansu Provincial Center for Disease Control and Prevention, Gansu Provincial Academy of Preventive Medicine, Lanzhou 730300, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Ji","sequence":"additional","affiliation":[{"name":"Gansu Provincial Center for Disease Control and Prevention, Gansu Provincial Academy of Preventive Medicine, Lanzhou 730300, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Lu","sequence":"additional","affiliation":[{"name":"Zhangye Municipal Center for Disease Control and Prevention, Zhangye 734000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxia","family":"Zuo","sequence":"additional","affiliation":[{"name":"Longxi County Center for Disease Control and Prevention, Longxi County Health Supervision Institute, Dingxi 748100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Nie","sequence":"additional","affiliation":[{"name":"Sinovac Biotech Co., Ltd., Beijing 100085, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Yao","sequence":"additional","affiliation":[{"name":"Sinovac Biotech Co., Ltd., Beijing 100085, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8284-1642","authenticated-orcid":false,"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Sinovac Biotech Co., Ltd., Beijing 100085, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yu","sequence":"additional","affiliation":[{"name":"Sinovac Biotech Co., Ltd., Beijing 100085, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"An","sequence":"additional","affiliation":[{"name":"Gansu Provincial Center for Disease Control and Prevention, Gansu Provincial Academy of Preventive Medicine, Lanzhou 730300, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"ref_1","unstructured":"Centers for Disease Control and Prevention (2026, August 26). About Global Polio Eradication, Available online: https:\/\/www.cdc.gov\/global-polio-vaccination\/about\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/polio\/global-polio-eradication.html#1."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.46234\/ccdcw2024.225","article-title":"Risk Assessments for Type 1 Wild Poliovirus and Type 2 Vaccine-Derived Poliovirus Importation and Transmission-China, 2023","volume":"6","author":"Kang","year":"2024","journal-title":"China CDC Wkly."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa1303368","article-title":"Identification and Control of a Poliomyelitis Outbreak in Xinjiang, China","volume":"369","author":"Luo","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_4","first-page":"174","article-title":"Vaccine Derived Poliovirus (VDPV)","volume":"31","author":"Mohanty","year":"2023","journal-title":"Infez. Med."},{"key":"ref_5","unstructured":"World Health Organization (2026, July 28). Meeting of the Strategic Advisory Group of Experts on Immunization, September 2024: Conclusions and Recommendations. Available online: https:\/\/www.who.int\/publications\/i\/item\/who-wer9949-719-740."},{"key":"ref_6","unstructured":"National Health Commission of the People\u2019s Republic of China (2026, July 28). National Immunization Program Vaccine Childhood Immunization Schedule and Instructions (2021 Edition), Available online: https:\/\/www.nhc.gov.cn\/jkj\/c100063\/202103\/c37c8bf6f00f446c8fa84f3134ac2360.shtml."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.trivac.2015.08.001","article-title":"Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies","volume":"4","author":"Resik","year":"2015","journal-title":"Trials Vaccinol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Fukushima, S., Nakano, T., Shimizu, H., and Hamada, A. (2022). Immunogenicity of Catch-Up Immunization with Conventional Inactivated Polio Vaccine among Japanese Adults. Vaccines, 10.","DOI":"10.3390\/vaccines10122160"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.imj.2022.12.002","article-title":"Coverage rates for diphtheria, tetanus, poliomyelitis, and pertussis age-specific booster recommendations in France: 2018 update of the real-world cohort analysis","volume":"2","author":"Verdier","year":"2023","journal-title":"Infect. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.15585\/mmwr.mm7249a3","article-title":"Use of Inactivated Polio Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023","volume":"72","author":"Kidd","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1016\/j.vaccine.2023.04.047","article-title":"Prevalence of poliovirus neutralizing antibodies in Italian population: A systematic review and meta-analysis","volume":"41","author":"Tafuri","year":"2023","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/21645515.2018.1547608","article-title":"Assessment of seroprevalence against poliovirus among Italian adolescents and adults","volume":"15","author":"Lupi","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1016\/j.vaccine.2018.09.023","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial","volume":"36","author":"Chu","year":"2018","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"ofz380","DOI":"10.1093\/ofid\/ofz380","article-title":"Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared with Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules with Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China","volume":"6","author":"Hu","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14760584.2021.1919091","article-title":"Cross-neutralization Capacity of Immune Serum from Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization against Multiple Individual Polioviruses","volume":"20","author":"Chu","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/infdis\/jiy736","article-title":"Immunogenicity and Safety of a Sabin Strain\u2013Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial","volume":"220","author":"Hu","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_17","unstructured":"Plotkin, S.A., Orenstein, W., Offit, P., and Edwards, K.M. (2018). Poliovirus Vaccine\u2013Live. Plotkin\u2019s Vaccines, Elsevier. [7th ed.]."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-065X.2010.00912.x","article-title":"Mechanisms that determine plasma cell lifespan and the duration of humoral immunity","volume":"236","author":"Amanna","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Fukushima, S., Nakano, T., Arita, M., Shimizu, H., and Hamada, A. (2025). Long-Term Persistence of Anti-Poliovirus Antibody Titers After Two-Dose Booster Immunization with Conventional Inactivated Poliovirus Vaccine Among Japanese Adults: 10-Year Observational Study. Vaccines, 13.","DOI":"10.3390\/vaccines13050447"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM200009143431103","article-title":"Trial of a supplemental dose of four poliovirus vaccines","volume":"343","author":"Sutter","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.4049\/jimmunol.171.10.4969","article-title":"Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination","volume":"171","author":"Crotty","year":"2003","journal-title":"J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/s41467-017-01901-w","article-title":"Plasma cell survival in the absence of B cell memory","volume":"8","author":"Hammarlund","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0952-7915(98)80162-3","article-title":"Long-lived plasma cells: A mechanism for maintaining persistent antibody production","volume":"10","author":"Slifka","year":"1998","journal-title":"Curr. Opin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of Protection Induced by Vaccination","volume":"17","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijid.2023.01.020","article-title":"Safety, immunogenicity, and lot-to-lot consistency of a multidose Sabin strain-based inactivated polio vaccine: A phase III, randomized, blinded, positive-control clinical trial in infants aged 2 months","volume":"130","author":"Feng","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Chu, K., Liu, Y., Liu, S., Shi, Y., Wang, J., Li, X., Jiao, P., and Pan, H. (2025). Sustained Immune Persistence Five Years Post-Completion of Four-Dose sIPV Vaccination. Vaccines, 13.","DOI":"10.3390\/vaccines13030253"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Thomassen, Y.E., van \u2018t Oever, A.G., van Oijen, M.G., Wijffels, R.H., van der Pol, L.A., and Bakker, W.A. (2013). Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083374"},{"key":"ref_28","first-page":"163","article-title":"Progress with inactivated poliovirus vaccines derived from the Sabin strains","volume":"105","author":"Doi","year":"2001","journal-title":"Dev. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.biologicals.2016.08.005","article-title":"Development of inactivated poliovirus vaccine from Sabin strains: A progress report","volume":"44","author":"Okayasu","year":"2016","journal-title":"Biologicals"},{"key":"ref_30","unstructured":"World Health Organization (2026, July 28). Global Action Plan for Poliovirus Containment. Available online: https:\/\/polioeradication.org\/wp-content\/uploads\/2022\/07\/WHO-Global-Action-Plan-for-Poliovirus-Containment-GAPIV.pdf."},{"key":"ref_31","unstructured":"World Health Organization (2026, July 28). Leave No One Behind: Guidance for Planning and Implementing Catch-Up Vaccination. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240016514."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.cmi.2025.01.019","article-title":"Duration of immunity after inactivated poliovirus vaccine: How many booster doses are needed?","volume":"31","author":"Blake","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.15585\/mmwr.mm7407a4","article-title":"Notes from the Field: Detection of Vaccine-Derived Poliovirus Type 2 in Wastewater\u2014Five European Countries, September-December 2024","volume":"74","author":"Huseynov","year":"2025","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_34","unstructured":"National Health Commission of the People\u2019s Republic of China (2026, July 28). Notice on Adjustment of the National Immunization Program Schedules for Poliovirus Vaccines and Measles-Containing Vaccines, Available online: https:\/\/www.nhc.gov.cn\/jkj\/c100063\/202001\/7c2ee2fd012b4038aa2e2ce9a96c6ca0.shtml."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/808\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:44:36Z","timestamp":1789389876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["vaccines14090808"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14090808","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}